Browse Title Index


 
Issue Title
 
Vol 2, No 3 (2010): Mol Cell Pharmacol FDA Approves a Cellular Immunotherapy for Men with Advanced Prostate Cancer Abstract   PDF
FDA News Release
 
Vol 5, No 2 (2013): Mol Cell Pharmacol FDA Approves Abraxane for Late-Stage Pancreatic Cancer Abstract   PDF
FDA News Release
 
Vol 5, No 3 (2013): Mol Cell Pharmacol FDA Approves Adempas to Treat Pulmonary Hypertension Abstract   PDF
FDA News Release
 
Vol 2, No 5 (2010): Mol Cell Pharmacol FDA Approves Botox to Treat Chronic Migraine Abstract   PDF
FDA News Release
 
Vol 9, No 3 (2017): Mol Cell Pharmacol FDA Approves CAR-T Cell Therapy to Treat Adults With Certain Types of Large B-cell Lymphoma Abstract   PDF
FDA News Release
 
Vol 3, No 2 (2011): Mol Cell Pharmacol FDA Approves Cialis to Treat Benign Prostatic Hyperplasia Abstract   PDF
FDA News Release
 
Vol 6, No 1 (2014): Mol Cell Pharmacol FDA Approves Cyramza for Stomach Cancer Abstract   PDF
FDA News Release
 
Vol 2, No 4 (2010): Mol Cell Pharmacol FDA Approves Drug for Chronic Drooling in Children Abstract   PDF
FDA News Release
 
Vol 1, No 3 (2009): Mol Cell Pharmacol FDA Approves Drug for Treatment of Aggressive Brain Cancer Abstract   PDF
FDA News Release
 
Vol 3, No 1 (2011): Mol Cell Pharmacol FDA Approves Drug to Reduce Risk of Preterm Birth in At-risk Pregnant Women Abstract   PDF
FDA News Release
 
Vol 9, No 1 (2017): Mol Cell Pharmacol FDA Approves Drug to Treat Duchenne Muscular Dystrophy Abstract   PDF
FDA News Release
 
Vol 9, No 1 (2017): Mol Cell Pharmacol FDA Approves Drug to Treat Parkinson’s Disease Abstract   PDF
FDA News Release
 
Vol 3, No 1 (2011): Mol Cell Pharmacol FDA Approves Edarbi to Treat High Blood Pressure Abstract   PDF
FDA News Release
 
Vol 7, No 2 (2015): Mol Cell Pharmacol FDA Approves Empliciti, a New Immune-stimulating Therapy to Treat Multiple Myeloma Abstract   PDF
FDA News Release
 
Vol 8, No 2 (2016): Mol Cell Pharmacol FDA approves Epclusa for treatment of chronic Hepatitis C virus infection Abstract   PDF
FDA News Release
 
Vol 3, No 2 (2011): Mol Cell Pharmacol FDA Approves Erwinaze to Treat a Form of Leukemia Abstract   PDF
FDA News Release
 
Vol 8, No 2 (2016): Mol Cell Pharmacol FDA approves first buprenorphine implant for treatment of opioid dependence Abstract   PDF
FDA News Release
 
Vol 9, No 2 (2017): Mol Cell Pharmacol FDA Approves First Cancer Treatment for Any Solid Tumor With a Specific Genetic Feature Abstract   PDF
FDA News Release
 
Vol 6, No 2 (2014): Mol Cell Pharmacol FDA Approves First Combination Pill to Treat Hepatitis C Abstract   PDF
FDA News Release
 
Vol 9, No 3 (2017): Mol Cell Pharmacol FDA Approves First Continuous Glucose Monitoring System for Adults Not Requiring Blood Sample Calibration Abstract   PDF
FDA News Release
 
Vol 8, No 3 (2016): Mol Cell Pharmacol FDA approves first drug for spinal muscular atrophy Abstract   PDF
FDA News Release
 
Vol 1, No 4 (2009): Mol Cell Pharmacol FDA Approves First Drug for Treatment of Peripheral T-cell Lymphoma Abstract   PDF
FDA News Release
 
Vol 8, No 1 (2016): Mol Cell Pharmacol FDA Approves First Drug to Show survival Benefit in Liposarcoma Abstract   PDF
FDA News Release
 
Vol 7, No 1 (2015): Mol Cell Pharmacol FDA Approves First Factor X Concentrate to Treat Patients with Rare Hereditary Bleeding Disorder Abstract   PDF
FDA News Release
 
Vol 3, No 2 (2011): Mol Cell Pharmacol FDA Approves First Generic Version of Cholesterol-Lowering Drug Lipitor Abstract   PDF
FDA News Release
 
Vol 1, No 3 (2009): Mol Cell Pharmacol FDA Approves First Maintenance Drug Therapy for Advanced Lung Cancer Abstract   PDF
FDA News Release
 
Vol 9, No 3 (2017): Mol Cell Pharmacol FDA Approves First Once-Monthly Buprenorphine Injection, a Medication-assisted Treatment Option for Opioid Use Disorder Abstract   PDF
FDA News Release
 
Vol 2, No 4 (2010): Mol Cell Pharmacol FDA Approves First Oral Drug to Reduce MS Relapses Abstract   PDF
FDA News Release
 
Vol 7, No 3 (2015): Mol Cell Pharmacol FDA Approves First Recombinant von Willebrand Factor to Treat Bleeding Episodes Abstract   PDF
FDA News Release
 
Vol 4, No 1 (2012): Mol Cell Pharmacol FDA Approves Gleevec for Expanded Use in Patients With Rare Gastrointestinal Cancer Abstract   PDF
FDA News Release
 
Vol 3, No 1 (2011): Mol Cell Pharmacol FDA Approves Head Lice Treatment for Children and Adults Abstract   PDF
FDA News Release
 
Vol 4, No 1 (2012): Mol Cell Pharmacol FDA Approves Inlyta to Treat Patients with a Type of Advanced Kidney Cancer Abstract   PDF
FDA News Release
 
Vol 8, No 3 (2016): Mol Cell Pharmacol FDA approves Jardiance to reduce cardiovascular death in adults with type 2 diabetes Abstract   PDF
FDA News Release
 
Vol 1, No 5 (2009): Mol Cell Pharmacol FDA Approves Kalbitor for Treating Potentially Life-Threatening Attacks of Hereditary Angioedema Abstract   PDF
FDA News Release
 
Vol 4, No 1 (2012): Mol Cell Pharmacol FDA Approves Kalydeco to Treat Rare Form of Cystic Fibrosis Abstract   PDF
FDA News Release
 
36 - 70 of 215 Items << < 1 2 3 > >> 



LumiText Publishing, P.O. Box 774, Ellicott City, MD 21041 

Copyright © 2008 LumiText Publishing. All rights reserved.